Ziopharm Oncology (ZIOP -6.2%) drops following a blog report in Forbes.com that accuses the...
Ziopharm Oncology (ZIOP -6.2%) drops following a blog report in Forbes.com that accuses the company of failing to disclose an FDA warning letter. The blogger, an investor short on the stock, says the FDA admonished a clinical investigator hired by ZIOP for multiple violations in a mid-stage study of Palifosfamide, its investigational cancer drug. The study in question has since advanced into a late-stage trial with results expected before 2013.
From other sites
Video at CNBC.com (May 18, 2016)
at CNBC.com (Jan 16, 2015)
at CNBC.com (Feb 14, 2013)
at CNBC.com (Jul 20, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs